Arch Biopartners doses first subject in trial of acute kidney injury treatment
Canadian clinical trial company Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of …
Canadian clinical trial company Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of …
AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of schizophrenia, failed to …
Neurogene’s stock has dropped by nearly 35% in pre-market trading after a patient in its Rett syndrome gene therapy trial …
UK-based pharmaceutical company Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to …
UK-based pharmaceutical company ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of dolutegravir/lamivudine (DTG/3TC) …
UK-based pharmaceutical company Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to …
UK-based pharmaceutical company ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of dolutegravir/lamivudine (DTG/3TC) …
An analyst has warned of likely instability in the US' healthcare systems following the election of Donald Trump as the …
According to the International Osteoporosis Foundation, osteoporosis is the most common bone disease. It affects one in five men and …
RAPT Therapeutics has called it quits on a clinical programme evaluating zelnecirnon (RPT193) in inflammatory disorders following feedback with the …
Gamma delta (γδ) T cells hold significant potential for unmet medical needs. Yet they are more challenging to source than …
Disc Medicine (Disc) has secured a $200m non-dilutive term loan facility from Hercules Capital to advance the clinical trials of …
As the US enters a new political era, experts predict that the pharmaceutical and clinical trials industry will have to …
Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a …
Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating advanced …